| Autor: |
Abdel Halim RM; Clinical Pathology Department, Faculty of Medicine Ain Shams University, Cairo, Egypt., Saber SM; Clinical Pathology Department, Faculty of Medicine Ain Shams University, Cairo, Egypt., Fahim NAE; Clinical Pathology Department, Faculty of Medicine Ain Shams University, Cairo, Egypt. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of medical microbiology [J Med Microbiol] 2023 Feb; Vol. 72 (2). |
| DOI: |
10.1099/jmm.0.001639 |
| Abstrakt: |
Introduction. Acinetobacter is one of the challenging drug-resistant organisms that can endanger patients' lives if not treated properly. Aim. This study was designed to investigate the activity of three synergistic antimicrobial combinations against extensive drug-resistant Acinetobacter isolates; ampicillin/sulbactam plus amikacin, ampicillin/sulbactam plus ciprofloxacin, and meropenem plus amikacin. Methodology. Minimum inhibitory concentrations of 100 XDR- Acinetobacter isolates were determined using the Vitek2 system. The broth micro-dilution method was performed to determine tigecycline MIC. Checkerboard assay was used to evaluate in vitro activity of the three antibiotic combinations. Results. MIC results by the Vitek 2C system revealed that all Acinetobacter isolates were resistant to all tested antibiotics except for colistin against which no resistance was reported. As for tigecycline, all isolates were susceptible. Regarding MIC results of each antibiotic, all isolates were resistant to meropenem and ciprofloxacin. While 95 % of isolates were resistant to both ampicillin/sulbactam and amikacin. The activities of antibiotic combinations by checkerboard assay were as follows: ampicillin/sulbactam plus amikacin was synergic in 52 %, additive 40 % and indifferent in 8 % of isolates, ampicillin/sulbactam plus ciprofloxacin was synergic in 40 %, additive 46 % and indifferent in 14 % of isolates, meropenem/amikacin combination was synergic in 22 %, additive in 49 % of isolates and indifferent in 29 % of isolates. No antagonistic activity was detected against any of the tested antibiotic combinations. Conclusion. Ampicillin/sulbactam plus amikacin showed the highest synergistic activity followed by ampicillin/sulbactam plus ciprofloxacin. This reflects the value of adding aminoglycosides to either of a β-lactam or quinolone. The tested antibiotic combinations are promising treatment options for XDR- Acinetobacter . |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
